LOXL2 and cancer: Previous studies indicated that the miR29 family inhibits cancer cell migration and invasion by directly targeting LOXL2 in several cancers (e.g., renal cell carcinoma, cervical cell carcinoma, and lung, head and neck squamous cell carcinoma) [5].